Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CIN-107 on Metformin Pharmacokinetics
NCT05526690Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of baxdrostat in hypertension (HTN) (2 arms), sponsored by AstraZeneca. Primary endpoints: Maximum plasma concentration, Time to Cmax and 4 more. Started Oct 2020; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05526690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526690.